- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04895683
Using Text Messages to Improve COVID-19 Vaccination Uptake
Can Behavioural-science Informed Text Messages Improve COVID-19 Vaccination Uptake in North West London? A RCT
COVID-19 vaccinations significantly reduce the risk of getting seriously ill or dying from COVID-19. Since December 2020, the UK has rolled out vaccinations according to the Joint Committee for Vaccinations and Immunity (JCVI) priority groups. However, despite data indicating that more than 90% of the UK population intends to get vaccinated, there are geographical and ethnic variations in vaccination acceptance. As younger cohorts with lower risk from COVID-19 become eligible for vaccination, it is expected that uptake rates may also be lower than they have been in previous cohorts.
It was recently announced that a national NHS text message service will be introduced to invite individuals eligible for the COVID-19 vaccine to book a vaccination appointment. Many GP practices and CCGs have already implemented text messages to invite eligible residents and patients for the vaccine.
However, recent research has shown that the message content of text messages inviting members of the public to other preventative health opportunities (e.g. personalised messages and GP-endorsements in cancer screening) can impact uptake.
This 3-arm randomised controlled trial will be conducted across the Central London (CL) Clinical Commissioning Group (CCG) which to-date has seen the lowest rates of COVID-19 vaccination uptake in the country. The study aims to investigate the most effective text message strategy to inform local, regional and national practice.
The intervention text message content to be tested is informed by behavioural science theory is personalised to include the recipient's name and GP practice name. All patients in the Central London CCG who are unvaccinated, aged 18-49, who have not declined the vaccine will be included as their cohort becomes eligible for vaccination according to the JCVI guidelines. The trial will compare the uptake of the COVID-19 vaccination by trial arm at 3 and 8 weeks after the intervention is deployed.
Přehled studie
Detailní popis
The COVID-19 vaccine is an effective way to reduce morbidity and mortality from COVID-19. Increasing uptake of the COVID-19 vaccine is a major public health priority. People's willingness to receive the COVID- 19 vaccine in the UK has been at record highs - 9 in 10 people said they would receive it when the NHS notifies them that it is their turn. However, evidence suggests that willingness to get vaccinated is lower amongst younger age groups and BAME populations. Additionally, high willingness to be vaccinated may not translate into high uptake, particularly as the vaccine rollout extends to younger, less vulnerable cohorts.
Uptake of the COVID-19 vaccine may be influenced by many factors, including personal beliefs such as perceived low personal risk from COVID-19, perceived social and cultural norms or a concerns around vaccine safety or efficacy. Additionally, process barriers, such as the effort required to attend an appointment may reduce vaccine uptake. With more than 95% of UK households having a mobile phone, text messages can be an effective way to improve uptake of healthcare services and medicine adherence. In particular, recent research has shown that reminder text messages about flu vaccination appointments can improve uptake by up to 10%, and that some messages may be more effective for specific groups. However, more research is needed to maximise the effectiveness of messages to increase uptake of the COVID-19 vaccine specifically and to explore how the effectiveness of messaging differs across different age and ethnicity groups.
The proposed research will determine which message strategy increases COVID-19 vaccine vaccination rates in the cohort aged between 18 and 49 years old as they become eligible for the vaccine according to JCVI categories.
During the trial, each cohort that newly becomes eligible to be vaccinated will be randomised to one of the five trial text message strategies.
The trial arms will include the current practice text message invitation which will act as the control and four intervention trial arms. The intervention text message strategies and message content have been based on behavioural science theory.
The usual care team will deploy the text messages according to the trial arm allocation. The vaccination status will be recorded in the patients electronic health record (EHR) as per usual practice. Researchers will have access to the pseudonymised datasets through a secure data platform which only holds pseudonomised data (see data Study Procedure section).
Analysis will measure and compare the vaccination uptake across trial arms.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Sarah Huf, MBBS PhD
- Telefonní číslo: 07496632732
- E-mail: s.huf@imperial.ac.uk
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Residents registered with a GP practice in the Central London (Westminster) Clinical Commissioning Group (CCG)
- Age 18-49
- Not previously invited for COVID-19 vaccination
Exclusion Criteria:
- Patients who have notified their GP that they wish to decline the COVID-19 vaccination.
- Patients' whose medical records report a severe allergy to medicines (as per the JCVI guidance)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Arm 1 - Control SMS
Control (current practice) text message invitation
|
Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
|
|
Experimentální: Arm 2 - Behavioural Science informed SMS content
Experimental text message invitation
|
Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
|
|
Experimentální: Arm 3 - Pre-alert and behavioural science informed SMS content
Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.
|
Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
COVID-19 vaccination uptake at 3 weeks
Časové okno: 3 weeks from invitation text message
|
COVID-19 vaccination uptake at 3 weeks
|
3 weeks from invitation text message
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
COVID-19 vaccination uptake at 8 weeks
Časové okno: 8 weeks from invitation text message
|
COVID-19 vaccination uptake at 8 weeks
|
8 weeks from invitation text message
|
|
COVID-19 vaccination uptake by demographics
Časové okno: 3 and 8 weeks
|
Exploratory analysis of COVID-19 vaccination uptake by demographics (age, gender, IMD decile, ethnicity, previous flu vaccination)
|
3 and 8 weeks
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Sarah Huf, MBBS PhD, Imperial College Health Care Trust
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Očekávaný)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 21SM6815
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Covid19
-
Anavasi DiagnosticsZatím nenabíráme
-
Ain Shams UniversityNábor
-
Israel Institute for Biological Research (IIBR)Dokončeno
-
Colgate PalmoliveDokončeno
-
Christian von BuchwaldDokončeno
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAktivní, ne nábor
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitatsspital ZurichZápis na pozvánku
-
Alexandria UniversityDokončeno
Klinické studie na Text message content
-
University of RochesterAmerican College of Chest PhysiciansDokončeno
-
Lovisenberg Diakonale HospitalNeznámýOtorinolaryngologická onemocnění | Poruchy sluchu | Poruchy spánku
-
Brooke Army Medical CenterUniversity of Colorado, DenverDokončenoObstrukce dýchacích cest | Intubace; Obtížné nebo neúspěšnéSpojené státy
-
University of UlmDokončenoStigma veřejné sebevraždyNěmecko
-
Tulane UniversityNational Institute of General Medical Sciences (NIGMS); LA CaTS Clinical Research...Dokončeno
-
University of CincinnatiFoundation for Informed Medical Decision MakingDokončenoIschemická choroba srdečníSpojené státy
-
Fundació d'investigació Sanitària de les Illes...DokončenoDiabetes mellitus, typ 2Španělsko
-
NHS Greater Glasgow and ClydeNeznámýKarcinom děložního čípku | Cervikální dysplazie
-
University of PennsylvaniaDokončenoRakovina tlustého střevaSpojené státy